Method of Using IL6 Antagonists with Mitoxantrone for Prostate Cancer

• US 20080081041A1
• Filed: 09/20/2007
• Published: 04/03/2008
• Est. Priority Date: 09/29/2006
• Status: Abandoned Application

• Current Assignee: Jeffrey Nemeth
• Original Assignee: Jeffrey Nemeth
• Inventors: Nemeth, Jeffrey
• Application Number:
  US11/858,418
• Publication Number:
  US 20080081041A1
• Time in Patent Office: Days
• US Class Current: 424/145.1
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/137 Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
• CPC Class Codes: A61K 39/39533 against materials from animals
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The invention is directed to a method of treating a subject diagnosed with prostate cancer which comprises co-administering mitoxantrone in combination with an IL-6 antagonist.

Claims

1. A method of treating a subject suffering from prostate cancer whereby said patient is in need of such treatment, which comprises co-administering an immunosuppressive 9,10-anthracenedione in combination with a neutralizing IL-6 antibody.

2. The method according to claim 1, in which the IL-6 antibody is cCLB8 or comprises cCLB8 or a fragment thereof.

3. The method according to claim 2 in which the antibody is a monoclonal antibody.

4. The method according to claim 2, in which the antibody or fragment binds to IL6.

5. The method according to claims 3 or 4, in which the antibody fragment is an Fab, Fab′

, or F(ab′

)2 fragment or derivative thereof.

6. The method according to claim 3, in which the monoclonal antibody competes with monoclonal antibody cCLB8 for binding to human IL6.

7. The method according to claim 3, in which the monoclonal antibody is administered intravenously

8. The method according to claim 3, in which the monoclonal antibody is administered in the amount of from 0.01 mg/kg to 12.0 mg/kg body weight.

9. The method according to claim 3, in which the monoclonal antibody is administered in a bolus dose followed by an infusion of said antibody.

10. The method according to claim 1, in which the subject is a human patient diagnosed with hormone refractive prostate cancer.

11. The method according to claim 1 in which the anthracenedione is mitoxantrone or pixantrone.

12. The method according to claim 1 in anthracenedione suppresses myelin degradation in a rat EAE model.

13. The method according to claim 1, in which the subject is diagnosed with prostate cancer and exhibits additional symptoms selected from the group consisting of hypercalcemia, metastatic lesions, or cachexia.

14. The method according to claim 1 in which the anti-IL6 antagonist is administered sequentially, serially, or concurrently with the immunosuppressive anthracenedione.

15. A method for inhibiting tumor growth in a mammal in need thereof comprising administering to the mammal in conjunction with an immunosuppressive anthracenedione, a monoclonal antibody or fragment thereof which prevents IL6 activation of signaling through membrane bound receptors in an amount effective to inhibit the growth of said tumor.

16. A method for treating a patient diagnosed with prostate cancer and having extracapsular extensive disease, comprising administering to the mammal in conjunction with an immunosuppressive anthracenedione, a monoclonal antibody or fragment thereof which prevents IL6 activation of signaling through membrane bound receptors in an amount effective to prevent the growth or reduce pain in said mammal.

17. A method of treating an IL-6 related disorder or condition, in a mammal in need of such treatment, which comprises co-administering an immunosuppressive anthracenedione in combination with an IL-6 antagonist.